AVEO Pharmaceuticals, Inc. (AVEO) Stock Formed Bullish Double Top Pattern. What To Expect?

January 16, 2018 - By Vivian Park

Investors sentiment increased to 1.32 in 2017 Q3. Its up 0.23, from 1.09 in 2017Q2. It improved, as 10 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 14 funds opened positions while 15 raised stakes. 59.90 million shares or 5.78% less from 63.58 million shares in 2017Q2 were reported.
Excalibur Mgmt owns 11,000 shares or 0.03% of their US portfolio. Guggenheim Capital Limited Liability Com invested in 20,642 shares or 0% of the stock. Cubist Systematic Strategies Ltd Limited Liability Company owns 11,325 shares for 0% of their portfolio. California Pub Employees Retirement Sys has invested 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Citigroup has invested 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Barclays Plc reported 319,900 shares or 0% of all its holdings. Northern Tru holds 206,033 shares. Cannell Peter B And Inc accumulated 0.01% or 109,875 shares. State Street Corporation has 92,375 shares for 0% of their portfolio. Bridgeway Capital Management owns 346,464 shares for 0.01% of their portfolio. Vanguard Group Inc has 4.26M shares for 0% of their portfolio. 683 Cap Mgmt Ltd holds 0.96% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 2.52 million shares. Manufacturers Life Insurance The reported 0% stake. Sphera Funds Mngmt Ltd owns 1.40 million shares. Polar Cap Limited Liability Partnership reported 4.13M shares.

The chart of AVEO Pharmaceuticals, Inc. (AVEO) shows a double top with $3.14 target or 9.00 % above today’s $2.88 share price. The 5 months chart pattern indicates low risk for the $442.20M company. It was reported on Jan, 16 by Finviz.com. If the $3.14 price target is reached, the company will be worth $39.80M more. Double tops are rare but powerful chart patterns.

The stock decreased 7.14% or $0.22 during the last trading session, reaching $2.88. About 3.31M shares traded or 81.28% up from the average. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 16.67% since January 16, 2017 and is downtrending. It has underperformed by 33.37% the S&P500.

Analysts await AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report earnings on March, 28. They expect $-0.03 EPS, up 72.73 % or $0.08 from last year’s $-0.11 per share. After $-0.02 actual EPS reported by AVEO Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 50.00 % negative EPS growth.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals has $7 highest and $200 lowest target. $5.67’s average target is 96.88% above currents $2.88 stock price. AVEO Pharmaceuticals had 11 analyst reports since March 30, 2016 according to SRatingsIntel. The rating was upgraded by Piper Jaffray to “Buy” on Monday, August 28. The firm has “Outperform” rating by FBR Capital given on Wednesday, March 30. The firm earned “Buy” rating on Thursday, October 5 by Piper Jaffray. FBR Capital maintained it with “Buy” rating and $5.0 target in Tuesday, January 16 report. On Thursday, December 7 the stock rating was maintained by FBR Capital with “Buy”. On Wednesday, August 9 the stock rating was maintained by Piper Jaffray with “Buy”. FBR Capital maintained the stock with “Buy” rating in Monday, June 26 report. As per Thursday, May 19, the company rating was initiated by Piper Jaffray.

Another recent and important AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news was published by Reuters.com which published an article titled: “SEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals exec” on January 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: